Given the high specificity and selectivity of MUC16 and MSLN as diagnostic markers, they have very high potential as theranostic targets to diagnose, treat, and monitor ovarian cancers (Zhao et al., 2023). This evidence concerns the gene MUC16 and ovarian carcinoma.